Cardiovascular (CV) outcome trials (CVOT) with glucagon-like peptide-1 receptor agonists (GLP-1RA), and sodium-glucose cotransporter 2 inhibitors (SGLT-2i) allowed to discover the renal benefits of these anti-diabetes compounds beyond their glucose-lowering efficacy [6, 8]. Here, GLP1R is linked to diabetes mellitus.